Natco Pharma Ltd (NATCOPHARM) — shareholding pattern, promoter holding, financials and share price

Natco Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as NATCOPHARM and on the BSE under scrip code 524816. Its ISIN is INE987B01026.

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business. [2]

Natco Pharma is a vertically integrated, R&D-led pharmaceutical company that develops, manufactures and markets complex finished dosage formulations (FDF) and APIs, with a strong presence in oncology and specialty generics across the US, India and multiple emerging markets; the company also invests in NCEs, cell and gene therapies to build a biotech pipeline alongside its generic business.

Q3 FY26 consolidated revenue was INR 705.4 crore with EBITDA of INR 216.8 crore and a 30.7% EBITDA margin; Q3 PAT was INR 151.3 crore and 9MFY26 PAT stands around INR 1,149.5 crore, showing NATCO Pharma has stabilized earnings despite loss of prior Revlimid tailwinds and is guiding full‑year revenue roughly around INR 4,200–4,300 crore.

Listed peers in Pharmaceuticals: ERIS Lifesciences Ltd, Caplin Point Laboratories Ltd, OneSource Specialty Pharma Ltd, Cohance Lifesciences Ltd, Alembic Pharmaceuticals Ltd, Jubilant Pharmova Ltd.